摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Bromo-1-[2-(4-fluorophenyl)-8,8-dimethyl-3-(4-methylanilino)-5,6-dihydroimidazo[1,2-a]pyrazin-7-yl]-2-methylpropan-1-one | 1261118-23-3

中文名称
——
中文别名
——
英文名称
2-Bromo-1-[2-(4-fluorophenyl)-8,8-dimethyl-3-(4-methylanilino)-5,6-dihydroimidazo[1,2-a]pyrazin-7-yl]-2-methylpropan-1-one
英文别名
——
2-Bromo-1-[2-(4-fluorophenyl)-8,8-dimethyl-3-(4-methylanilino)-5,6-dihydroimidazo[1,2-a]pyrazin-7-yl]-2-methylpropan-1-one化学式
CAS
1261118-23-3
化学式
C25H28BrFN4O
mdl
——
分子量
499.426
InChiKey
IHJOBXZRIWCJKE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5
  • 重原子数:
    32
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    50.2
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-Bromo-1-[2-(4-fluorophenyl)-8,8-dimethyl-3-(4-methylanilino)-5,6-dihydroimidazo[1,2-a]pyrazin-7-yl]-2-methylpropan-1-one 在 sodium azide 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 2.0h, 以75%的产率得到2-Azido-1-[2-(4-fluorophenyl)-8,8-dimethyl-3-(4-methylanilino)-5,6-dihydroimidazo[1,2-a]pyrazin-7-yl]-2-methylpropan-1-one
    参考文献:
    名称:
    Imidazolopiperazines: Lead Optimization of the Second-Generation Antimalarial Agents
    摘要:
    On the basis of the initial success of optimization of a novel series of imidazolopiperazines, a second generation of compounds involving changes in the core piperazine ring was synthesized to improve antimalarial properties. These changes were carried out to further improve the potency and metabolic stability of the compounds by leveraging the outcome of a set of in vitro metabolic identification studies. The optimized 8,8-dimethyl imidazolopiperazine analogues exhibited improved potency, in vitro metabolic stability profile and, as a result, enhanced oral exposure in vivo in mice. The optimized compounds were found to be more efficacious than the current antimalarials in a malaria mouse model. They exhibit moderate oral exposure in rat pharmacokinetic studies to achieve sufficient multiples of the oral exposure at the efficacious dose in toxicology studies.
    DOI:
    10.1021/jm300041e
  • 作为产物:
    参考文献:
    名称:
    Imidazolopiperazines: Lead Optimization of the Second-Generation Antimalarial Agents
    摘要:
    On the basis of the initial success of optimization of a novel series of imidazolopiperazines, a second generation of compounds involving changes in the core piperazine ring was synthesized to improve antimalarial properties. These changes were carried out to further improve the potency and metabolic stability of the compounds by leveraging the outcome of a set of in vitro metabolic identification studies. The optimized 8,8-dimethyl imidazolopiperazine analogues exhibited improved potency, in vitro metabolic stability profile and, as a result, enhanced oral exposure in vivo in mice. The optimized compounds were found to be more efficacious than the current antimalarials in a malaria mouse model. They exhibit moderate oral exposure in rat pharmacokinetic studies to achieve sufficient multiples of the oral exposure at the efficacious dose in toxicology studies.
    DOI:
    10.1021/jm300041e
点击查看最新优质反应信息

文献信息

  • COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES
    申请人:Chatterjee Arnab K.
    公开号:US20110059934A1
    公开(公告)日:2011-03-10
    The invention provides a class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent malaria.
    本发明提供了一类化合物,包括该类化合物的药物组合物以及使用该类化合物治疗或预防疟疾的方法。
  • COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
    申请人:Chatterjee Arnab K.
    公开号:US20130281403A1
    公开(公告)日:2013-10-24
    The invention provides a class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent malaria.
    本发明提供了一类化合物,包括该类化合物的药物组合物和使用该类化合物治疗或预防疟疾的方法。
  • COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASE
    申请人:Chatterjee Arnab K.
    公开号:US20160108051A1
    公开(公告)日:2016-04-21
    The invention provides a class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent malaria.
    本发明提供了一类化合物,包括这些化合物的药物组合物和使用这些化合物治疗或预防疟疾的方法。
  • Imidazo[1,2a]pyrazines and compositions comprising them for the treatment of parasitic diseases
    申请人:IRM LLC
    公开号:EP2737927A1
    公开(公告)日:2014-06-04
    The invention provides compounds of formula Ia, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent malaria.
    本发明提供了式 Ia 化合物、包含此类化合物的药物组合物以及使用此类化合物治疗或预防疟疾的方法。
  • US8557801B2
    申请人:——
    公开号:US8557801B2
    公开(公告)日:2013-10-15
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺